Trevi Therapeutics, Inc. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Trevi Therapeutics, Inc. (TRVI) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $34.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2019-11-14
- 2019-09-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $34.00K.
- 2019-06-30: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $68.00K.
- 2019-03-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $102.00K.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2019-09-30 | $34.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $68.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $102.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |